Factors Affecting Diabetes Control And Dyslipidaemia Among Type 2 Diabetes Mellitus Patients In Hospital Universiti Sains Malaysia [RC660. E25 2003 f rb]. by Akhtar Mohammad, Eid Mohammad
  
FACTORS AFFECTING DIABETES CONTROL 
AND DYSLIPIDAEMIA AMONG TYPE 2 
DIABETES MELLITUS PATIENTS IN HOSPITAL 
UNIVERSITI SAINS MALAYSIA  
 
 
 
 
DR. EID MOHAMMAD s/o AKHTAR MOHAMMAD 
 
 
 
 
UNIVERSITI SAINS MALAYSIA  
2003 
  
 
 
FACTORS AFFECTING DIABETES CONTROL AND 
DYSLIPIDAEMIA AMONG TYPE 2 DIABETES MELLITUS 
PATIENTS IN HOSPITAL UNIVERSITI SAINS MALAYSIA  
 
 
 
 
by 
 
 
 
 
DR. EID MOHAMMAD s/o AKHTAR MOHAMMAD 
(MD Kabul University, Afghanistan) 
 
 
 
 
Thesis submitted in fulfilment of the 
requirements for the degree 
of Master of Science 
 
 
January 2003 
  
 
ACKNOWLEDGEMENT 
 
 
I would like to express my gratitude to all those who have contributed to this 
work. First, I should grant my deepest appreciation and sincere thanks to my main 
supervisor, PROFESSOR DR. MAFAUZY MOHAMED for his supervision and 
support throughout my study. 
My sincere and special thanks to my co-supervisor, ASSOCIATE 
PROFESSOR DR. FARIDAH ABDUL RASHID for her great help, continuous 
assistance, invaluable encouragement, guidance, and comments in the writing of this 
thesis.  
 
My respects and thanks are due to all the staff at the Diabetes Outpatient Clinic 
and at Clinical Trial Unit especially SISTER RUBIAH OTHMAN and EN. MANAF 
YUSOF for their friendly cooperation. Thanks are also due to the head and staff of 
Chemical Pathology Department (Routine Lab) and Endocrine Lab, HUSM. I would 
like to extent my thanks to MR. ZULKIFLI BIN ISMAIL for his excellent technical 
assistance. My deepest appreciation to DR. THAN WINN for his great help with 
statistical analysis. Thanks are also due to library staff and workers at the postgraduate 
computer lab who made all facilities available for my use. 
Nevertheless, gratitude is also due to the Islamic Development Bank for sponsoring 
my study.  
 ii
 
 
 
 
DEDICATED TO MY PARENTS, 
BELOVED WIFE, AND MY CHILDREN 
AYSHA & ABDUL-WASI. 
 
 
 
 رلاب وا روم امز باتآ هغد ,يخش 
 عساولادبع وا هشياع ونودلاوا وا
موآ ءادها هت. 
  
 
TABLE OF CONTENT 
 
 
 Page  
ACKNOWLEDGEMENT  іі
TABLE OF CONTENT ііі
LIST OF TABLES х
LIST OF FIGURES хv
LIST OF ABBREVIATIONS xxi
ABSTRACT xxvi
ABSTRAK xxviii
  
CHAPTER 1 INTRODUCTION  1
  
1.1 Prevalence of type 2 diabetes  2
1.2 Diagnosis of diabetes mellitus 6
1.3 Classification of diabetes mellitus 9
1.4 Hyperglycemia 12
 1.4.1 Fasting plasma glucose (FPG) 12
 1.4.2 Glycated hemoglobin (A1C) 13
1.5 Diabetic dyslipidaemia 15
1.6 Hypertension 27
 iii
1.7 Treatment for diabetes mellitus 29
 1.7.1 Treatment for controlling of blood glucose 29
  1.7.1.1 Clinical targets for glycaemic control in people with 
diabetes 30
 1.7.2 Management of diabetic dyslipidaemia 31
  1.7.2.1 Goals of therapy for lipid profile in diabetic patients 32
  1.7.2.2 Nonpharmacological strategies 33
  1.7.2.3 Antidiabetic agents and modification of lipoprotein 
levels 34
  1.7.2.4 Lipid-lowering drug therapy 35
  1.7.2.5 Lipid lowering drugs 39
1.8 Aim of the study   41
1.9 Objectives   42
  
CHAPTER 2 METHODOLOGY  43
   
2.1 Ethical approval 44
2.2 Study design  44
2.3 Selection of patients 44
2.4 Inclusion and exclusion criteria 46
2.5 Definition of clinical conditions and terms  46
2.6 Physical examination 50
 2.6.1 Height and body weight measurements 50
 2.6.2 Blood pressure measurement 50
2.7 Collection of blood sample 51
 iv
2.8 Biochemical analysis 52
 2.8.1 Determination of glucose 52
 2.8.2 Determination of glycated hemoglobin 53
 2.8.3 Determination of total cholesterol 54
 2.8.4 Determination of HDL cholesterol 55
 2.8.5 Calculation of VLDL cholesterol 55
 2.8.6 Calculation of LDL cholesterol 56
 2.8.7 Determination of triglycerides 57
2.9 Statistical analysis 58
 2.9.1 Calculation of sample size 58
 2.9.2 Analysis of data 61
  
CHAPTER 3 RESULTS  62
  
3.1 Clinical targets for the control of diabetes mellitus in type 2 diabetic 
patients attending Diabetes Clinic in HUSM 63
 3.1.1 Characteristics of type 2 diabetic patients 63
 3.1.2 Clinical targets for glycaemic control in type 2 diabetes 80
  3.1.2.1 Gender and glycaemic control  80
  3.1.2.2 Ethnicity and glycaemic control  82
  3.1.2.3 Age and glycaemic control  83
  3.1.2.4 Duration of diabetes and glycaemic control  85
  3.1.2.5 Family history of diabetes and glycaemic control 86
  3.1.2.6 Smoking and glycaemic control  87
  3.1.2.7 BMI and glycaemic control  88
 v
  3.1.2.8 Multiple Logistic Regression Analysis (A1C) 91
 3.1.3 Clinical targets for BMI (obesity) in type 2 diabetes 92
  3.1.3.1 Gender and BMI  92
  3.1.3.2 Ethnicity and BMI  94
  3.1.3.3 Age and BMI  95
  3.1.3.4 Duration of diabetes and BMI  98
  3.1.3.5 Family history of diabetes and BMI  99
  3.1.3.6 Smoking and BMI  100
  3.1.3.7 Multiple Logistic Regression Analyses 101
 3.1.4 Clinical targets for blood pressure in type 2 diabetes 102
  3.1.4.1 Antihypertensive treatment and control of blood 
pressure  103
  3.1.4.2 Gender and control of blood pressure  105
  3.1.4.3 Ethnicity and control of blood pressure 107
  3.1.4.4 Age and control of blood pressure 109
  3.1.4.5 Duration of diabetes and control of blood pressure 111
  3.1.4.6 Family history of diabetes and control of blood 
pressure 113
  3.1.4.7 Smoking and control of blood pressure 115
  3.1.4.8 BMI and control of blood pressure 117
  3.1.4.9 A1C and control of blood pressure 119
  3.1.4.10 Multiple Logistic Regression Analyses 121
 3.1.5 Clinical targets for lipids in type 2 diabetes 122
  3.1.5.1 Lipid-lowering drug therapy 122
 vi
  3.1.5.2 Proportion of patients with none, one, two, three, or 
four lipid values outside of the clinical target 126
  3.1.5.3 Proportion of male and female patients with one, two, 
three, or four lipid values outside of clinical target  128
  3.1.5.4 Proportion of patients with one, two, three, or four 
lipid values outside of clinical target in three 
glycaemic control groups by A1C 130
  3.1.5.5 Multiple Logistic Regression Analyses 132
  
3.2 Pattern of diabetic dyslipidaemia according to American Diabetes 
Association (ADA) classification of lipoprotein into CVD risk categories  134
  
3.3 Lipid profile of type 2 diabetic patients who are not on anti-lipid therapy 139
 3.3.1 Characteristics of type 2 diabetic subjects who are not on anti-
lipid therapy 139
 3.3.2 Classification of total, HDL, LDL cholesterol and triglycerides 
according to NCEP, ATP III  149
 3.3.3 Distribution of lipid profile in men and women  155
 3.3.4 Ethnicity and lipid profile 159
 3.3.5 Age and lipid profile 161
 3.3.6 Duration of diabetes and lipid profile 165
 3.3.7 Family history of diabetes mellitus and lipid profile 170
 3.3.8 Smoking and lipid profile 171
 3.3.9 BMI and lipid profile 172
 3.3.10 Fasting plasma glucose and lipid profile 181
 vii
 3.3.11 Glycated hemoglobin and lipid profile 186
  
3.4 Effect of glycaemic control on lipid profile in type 2 diabetic patients 190
 3.4.1 Difference in mean lipid profiles of type 2 diabetic patients 
according to different levels of fasting plasma glucose 190
  3.4.1.1 Difference in mean lipid profiles at fasting plasma 
glucose of  7 mmol/L  190
  3.4.1.2 Difference in mean lipid profiles at fasting plasma 
glucose of 8 mmol/L 192
  3.4.1.3 Difference in mean lipid profiles at fasting plasma 
glucose of 9 mmol/L 193
  3.4.1.4 Difference in mean lipid profiles at fasting plasma 
glucose of 10 mmol/L 195
 3.4.2 Difference in mean lipid profiles of type 2 diabetics patients 
according to different levels of A1C 199
  3.4.2.1 Difference in mean lipid profiles at A1C of  7 % 200
  3.4.2.2 Difference in mean lipid profiles at A1C of  8 % 201
  3.4.2.3 Difference in mean lipid profiles at A1C of  9 % 204
  3.4.2.4 Difference in mean lipid profiles at A1C of  10 % 208
  3.4.2.5 Difference in mean lipid profiles in three glycaemic 
control groups by A1C 212
  
 
 
 
 viii
 ix
CHAPTER 4 DISCUSSION 219
  
 4.1 Glycaemic control (A1C) 220
 4.2 Body Mass Index (BMI) 221
 4.3 Blood pressure 222
 4.4 Lipid profile 224
  4.4.1 Prevalence of dyslipidaemia 224
  4.4.2 Pattern of dyslipidaemia in type 2 diabetic patients  224
  4.4.3 Pattern of dyslipidaemia in type 2 diabetic patients 
who are not on any anti-lipid therapy 226
  4.4.4 Contributing factors 227
 4.5 Limitations of current study 229
  
CHAPTER 5 SUMMARY AND CONCLUSION 230
  
 5.1 Summary and conclusion 231
 5.2 Recommendations for future research 233
 
REFERENCES 234
APPENDICES 248
 Appendix 1 OFFER LETTER 249
 Appendix 2 CONSENT FORM 250
 Appendix 3 DATA COLLECTION FORM 251
 Appendix 4 LIST OF PUBLICATIONS 252
 
  
 
LIST OF TABLES 
 
  Page  
Table 1.1  Criteria for testing for diabetes in asymptomatic adults 4
Table 1.2 Criteria for testing for type 2 diabetes in children 5
Table 1.3 Fasting and 2-h post-load glucose values for diagnosis of 
diabetes mellitus and other categories of hyperglycaemia 8
Table 1.4 Prevalence of diabetic dyslipidaemia in Malaysia 21
Table 1.5 Effect of Statin Therapy on CHD: Clinical Events Trials 23
Table 1.6 Outcome of clinical events trials of statin in prevention of new 
coronary heart disease (CHD) events 25
Table 1.7 Clinical events trials of fibrate drugs involving patients with 
diabetes 26
Table 1.8 Glycaemic control for non-pregnant individuals with diabetes 30
Table 1.9 Treatment decisions based on LDL cholesterol levels in adults 
with diabetes mellitus 36
Table 1.10 Order of priorities for treatment of diabetic dyslipidaemia in 
adults 38
Table 2.1 Method for recruiting diabetic patients 45
Table 3.1 Patient classification by age groups 63
Table 3.2 Classification of patient according to the duration of diabetes 65
Table 3.3 Classification of type 2 diabetic patients by BMI  67
 x
Table 3.4 Classification of type 2 diabetic patients by blood pressure 67
Table 3.5 FPG, A1C and lipid profiles of type 2 diabetic patients 69
Table 3.6 Distributions of patients with microvascular, macrovascular, 
and microvascular + macrovascular complications of diabetes 70
Table 3.7 Distribution of patients with one, two, three, or four 
complications 71
Table 3.8 Use of anti diabetic drugs 73
Table 3.9 Use of lipid-lowering drugs 74
Table 3.10 Use of antihypertensive drugs 75
Table 3.11 Distribution of type 2 diabetic patients receiving anti diabetic, 
lipid-lowering and antihypertensive drugs 76
Table 3.12 Clinical summary of type 2 diabetic patients 79
Table 3.13 Distribution of patients with FPG and A1C values at clinical 
and not at clinical target 80
Table 3.14 Multiple logistic regression analysis examining the influence 
of age, duration of diabetes, BMI, ethnicity, and gender on the 
probability of having A1C levels outside of recommended 
clinical targets 91
Table 3.15 Distribution of male and female patients with BMI values at 
clinical and not at clinical targets 93
Table 3.16 Distribution of patients with BMI values at clinical and not at 
clinical target according to ethnicity 94
Table 3.17 Multiple logistic regression analysis examining the influence 
of age, duration of diabetes, A1C, ethnicity, and gender on the 
probability of having BMI levels outside of clinical targets 101
 xi
Table 3.18 Distribution of patients with Blood Pressure at clinical targets 
and not at clinical target in treated and non-treated groups 102
Table 3.19 Multiple logistic regression analysis examining the influence 
of age, duration of diabetes, BMI, A1C, ethnicity, and gender 
on the probability of having systolic blood pressure levels 
outside of recommended clinical targets 121
Table 3.20 Distribution of patients with lipid values at clinical and outside 
of clinical target in treated (for dyslipidaemia) and non-treated 
groups of patients  123
Table 3.21 Distribution of patients with total, HDL, LDL cholesterol and 
triglycerides at clinical and outside of clinical target in treated 
(for dyslipidaemia) and non-treated groups of patients 125
Table 3.22 Distribution of patients who had none, one, two, three, or all 
four lipid values outside of clinical targets 127
Table 3.23 Multiple logistic regression analysis examining the influence 
of age, duration of diabetes, BMI, A1C, ethnicity, and gender 
on the probability of having total, HDL, LDL cholesterol and 
triglycerides levels outside of recommended clinical targets  132
Table 3.24 Distribution of patients with high, borderline, and low risk 
HDL, LDL cholesterol and triglycerides according to ADA 
classification 134
Table 3.25 Distribution of patients who had none, one, two, or all three 
lipids values outside of recommended clinical target  137
Table.3.26 Distribution of type 2 diabetic patients with and without the 
three types of dyslipidaemia  138
 xii
Table 3.27 Basic characteristics of type 2 diabetic patients who are not on 
anti-lipid therapy 139
Table 3.28 FPG, A1C and lipid profiles of type 2 diabetic patients who are 
not on anti-lipid therapy 141
Table 3.29 Association between lipid parameters among type 2 diabetic 
patients 148
Table 3.30 Distribution of type 2 diabetic patients according to NCEP 
ATP III classification 150
Table 3.31 Lipid profile of type 2 diabetic patients with and without 
dyslipidaemia 151
Table 3.32 Distribution of type 2 diabetic patients with none, one, two, 
three or four criteria of dyslipidaemia 153
Table 3.33 Distribution of type 2 diabetic patients who are not on anti-
lipid therapy with and without the three types of dyslipidaemia 154
Table 3.34 Lipid profile of male and female type 2 diabetic patients 156
Table 3.35 Lipid profile of Malay, Chinese, and Indian subjects  160
Table 3.36 Lipid profile of Malay and non-Malay type 2 diabetic patients 160
Table 3.37 Univariate correlation coefficient and P-values of total, HDL, 
LDL, VLDL cholesterol and triglycerides against age 162
Table 3.38 Lipid profile of three age groups (< 50 years, 50 – 59 years, 
and > 59 years) of type 2 diabetic patients 164
Table 3.39 Association between lipid profile and duration of diabetes in 
type 2 diabetic patients 166
Table 3.40 Lipid profile of type 2 diabetic patients grouped by duration of 
diabetes 169
 xiii
 xiv
Table 3.41 Lipid profile of type 2 diabetic patients with/without family 
history of diabetes mellitus 170
Table 3.42 Lipid profile of smoker and non-smoker patients 171
Table 3.43 Lipid profile and BMI in type 2 diabetic patients 175
Table 3.44 Lipid profile and three BMI categories (good, acceptable and 
poor) 180
Table 3.45 Lipid profile and FPG in type 2 diabetic patients 182
Table 3.46 Univariate analyses of lipid profile and A1C 186
Table 3.47 Lipid profile of type 2 diabetic patients with good and poor 
glycaemic control (at FPG of 7 mmol/L) 191
Table 3.48 Lipid profiles of type 2 diabetic patients with good and poor 
glycaemic control (at FPG of 8 mmol/L) 192
Table 3.49 Lipid profiles type 2 diabetic patients grouped as FPG < 9 and 
≥ 9 mmol/L 194
Table 3.50 Lipid profiles of type 2 diabetic patients grouped as FPG < 10 
and ≥ 10 mmol/L 198
Table 3.51 Lipid profile of patients grouped as A1C < 7 % and ≥ 7 % 200
Table 3.52 Lipid profile of patients grouped as A1C < 8 % and ≥ 8 % 201
Table 3.53 Lipid profile of patients grouped as A1C < 9 % and ≥ 9 % 204
Table 3.54 Lipid profile of patients grouped as A1C < 10 % and ≥ 10 % 208
Table 3.55 Lipid profile of type 2 diabetic patients with good, acceptable 
and poor glycaemic control 213
Table 3.56 Difference in mean lipid profile between three (good, 
acceptable and poor) glycaemic control groups of patients 214
 
  
 
LIST OF FIGURES 
 
 
  Page  
Figure 1.1 Unstandardized (casual, random) blood glucose values in the 
diagnosis of diabetes mellitus 7
Figure 1.2   Disorders of glycaemia: aetiological types and clinical stages 10
Figure 1. 3 The pathophysiologic basis for diabetic dyslipidemia and its 
relation to insulin resistance 17
Figure 3.1 Age distribution of type 2 diabetic patients 64
Figure 3.2 Distribution of the duration of diabetes in type 2 diabetic 
patients 65
Figure 3.3 Distribution of BMI in type 2 diabetic patients 66
Figure 3.4 Distribution of SBP in type 2 diabetic patients 68
Figure 3.5 Distribution of DBP in type 2 diabetic patients 68
Figure 3.6 Types of eye complications in type 2 diabetic patients 72
Figure 3.7 Frequency of male and female subjects with A1C at clinical 
target and outside of clinical target level 81
Figure 3.8 Distribution of  % A1C in Malays and other ethnic groups 82
Figure 3.9 Association of A1C with age 83
Figure 3.10 Mean % A1C of three age groups of patients 84
 xv
Figure 3.11 Percentage of patients with A1C level at clinical and outside 
of clinical target in four groups by duration of diabetes 85
Figure 3.12 Proportions of patients with A1C values at clinical target and 
outside of clinical target in two groups (with and without 
positive family history of diabetes)  86
Figure 3.13 Proportion of smoker and non-smoker patients with A1C 
values at clinical target and outside of clinical target level 87
Figure 3.14 Association between BMI and A1C 88
Figure 3.15 Frequency of the patients with % A1C level at clinical target 
and outside of clinical target in two BMI groups 89
Figure 3.16 Frequency of the patients with % A1C level at clinical target 
and outside of clinical target in three BMI groups 90
Figure 3.17 Distribution of BMI in male and female subjects 92
Figure 3.18 Proportion of patients with BMI values at clinical target and 
outside of clinical target in three age groups 96
Figure 3.19 Mean BMI values of patients in three age groups  96
Figure 3.20 Association of BMI with age 97
Figure 3.21 Association of BMI with duration of diabetes 98
Figure 3.22 Proportion of patients with BMI values at clinical target and 
outside of clinical target in two groups (with and without 
positive family history of diabetes) 99
Figure 3.23 Proportion of smoker and non-smoker with BMI values at 
clinical target and outside of clinical target level 100
Figure 3.24 Frequency of patients with SBP at clinical and outside of 
clinical target in antihypertensive therapy groups 103
 xvi
Figure 3.25 Frequency of patients with DBP at clinical and outside of 
clinical target in antihypertensive therapy groups 104
Figure 3.26 Frequency of male and female subjects with SBP at clinical 
and outside of clinical target 105
Figure 3.27 Frequency of male and female subjects with DBP at clinical 
and outside of clinical target 106
Figure 3.28 Frequency of patients with SBP at clinical and outside of 
clinical target in ethnic groups 107
Figure 3.29 Frequency of patients with DBP at clinical and outside of 
clinical target in ethnic groups 108
Figure 3.30 Linear association between SBP and age of patients 109
Figure 3.31 Proportion of patients with SBP at clinical and outside of 
clinical target in three age groups 110
Figure 3.32 Frequency of patients having SBP at clinical and outside of 
clinical target grouped according to the duration of diabetes 111
Figure 3.33 Frequency of patients having DBP at clinical and outside of 
clinical target grouped according to the duration of diabetes 112
Figure 3.34 Proportions of patients with SBP at clinical and outside of 
clinical target in two groups (with positive family history of 
diabetes and negative family history of diabetes) 113
Figure 3.35 Proportions of patients with DBP at clinical and outside of 
clinical target in two groups (with positive family history of 
diabetes and negative family history of diabetes) 114
Figure 3.36 Frequency of smoker and non-smoker patients with SBP at 
clinical and outside of clinical target level 115
 xvii
Figure 3.37 Frequency of smoker and non-smoker patients with DBP at 
clinical and outside of clinical target level 116
Figure 3.38 Frequency of the patients with SBP at clinical and outside of 
clinical target in two BMI groups 117
Figure 3.39 Frequency of the patients with DBP at clinical and outside of 
clinical target in two BMI groups 118
Figure 3.40 Frequency of patients with SBP at clinical and outside of 
clinical target according to glycaemic control 119
Figure 3.41 Frequency of patients with DBP at clinical and outside of 
clinical target according to glycaemic control 120
Figure 3.42 Frequency of male and female subjects with one, two, three, 
and four lipid values outside of clinical target 129
Figure 3.43 Frequency of patients with one, two, three, or four lipid 
values outside of clinical target and good, acceptable, or poor 
glycaemic control 131
Figure 3.44 Association between FPG and A1C 140
Figure 3.45 Distribution of total cholesterol in type 2 diabetic patients 142
Figure 3.46 Distribution of HDL cholesterol in type 2 diabetic patients 143
Figure 3.47 Distribution of LDL cholesterol in type 2 diabetic patients 144
Figure 3.48 Distribution of VLDL cholesterol in type 2 diabetic patients 145
Figure 3.49 Distribution of triglycerides in type 2 diabetic patients 146
Figure 3.50 Sex distribution in type 2 diabetic patients 155
Figure 3.51 Distribution of total cholesterol in male and female subjects 157
Figure 3.52 Ethnic distribution of type 2 diabetic patients 159
Figure 3.53 Age distribution in type 2 diabetic patients 161
 xviii
Figure 3.54 Mean LDL cholesterol in age groups < 50 and 50 – 59 years 163
Figure 3.55 Duration of diabetes among type 2 diabetic patients 165
Figure 3.56 Distribution of patients according to the duration of diabetes 167
Figure 3.57 Distribution of BMI in type 2 diabetic patients 172
Figure 3.58 Association between VLDL cholesterol and BMI in type 2 
diabetic patients 173
Figure 3.59 Association between triglycerides and BMI  174
Figure 3.60 Distribution of type 2 diabetic patients in three BMI groups 178
Figure 3.61 Distribution of FPG in type 2 diabetic patients 181
Figure 3.62 Association between triglycerides and FPG among type 2 
diabetic patients 183
Figure 3.63 Association between total cholesterol and FPG in type 2 
diabetic patients 184
Figure 3.64 Association between LDL cholesterol and FPG in type 2 
diabetic patients 185
Figure 3.65 Distribution of A1C in type 2 diabetic patients 187
Figure 3.66 Association between A1C and triglycerides 189
Figure 3.67 Distribution of total cholesterol in type 2 diabetic patients 
based on fasting plasma glucose of 10 mmol/L 195
Figure 3.68 Distribution of mean LDL cholesterol in type 2 diabetic 
patients based on fasting plasma glucose of 10 mmol/L 196
Figure 3.69 Distribution of mean triglycerides in type 2 diabetic patients 
based on fasting plasma glucose of 10 mmol/L 197
Figure 3.70 Difference in mean total cholesterol between two groups of 
patients based on glycaemic control (A1C) of 8 % 202
 xix
 xx
Figure 3.71 Distribution of LDL cholesterol of type 2 diabetic patients 
based on glycaemic control (A1C) of 8 % 203
Figure 3.72 Distribution of total cholesterol of type 2 diabetic patients 
based on glycaemic control (A1C) of 9 % 205
Figure 3.73 Mean LDL cholesterol of type 2 diabetic patients based on 
glycaemic control (A1C) of 9 % 206
Figure 3.74 Mean triglycerides of type 2 diabetics patients based on 
glycaemic control (A1C) of 9 % 207
Figure 3.75 Mean total cholesterol of type 2 diabetic patients based on 
glycaemic control (A1C) of 10 % 209
Figure 3.76 Mean LDL cholesterol of type 2 diabetic patients based on 
glycaemic control (A1C) of 10 % 210
Figure 3.77 Distribution of triglycerides in type 2 diabetic patients based 
on glycaemic control (A1C) of 10 % 211
Figure 3.78 Distribution of type 2 diabetic patients in three glycaemic 
control groups 212
Figure 3.79 Mean total cholesterol of type 2 diabetic patients in three 
glycaemic control groups (A1C < 7 %, 7 – 10 %, and >10 %) 215
Figure 3.80 Distribution of LDL cholesterol in good, acceptable and poor 
glycaemic control groups of type 2 diabetic patients 216
Figure 3.81 Mean triglycerides of good, acceptable and poor glycaemic 
control groups of type 2 diabetic patients 218
 
  
 
LIST OF ABBREVIATIONS 
 
 
Abbreviation Full 
2-h PG two-hour postprandial plasma glucose 
4S Scandinavian Simvastatin Survival Study 
A1C glycated hemoglobin (HbA1c) 
ACE angiotensin-converting enzyme 
ACEI ACE inhibitor 
ADA American Diabetes Association 
ADM atypical diabetes mellitus 
AFCAPS/TexCAPS Air Force/Texas Coronary Prevention Study 
A-II angiotensin II 
ANCOVA analysis of covariance 
ANOVA analysis of variance 
apo apolipoprotein 
apo A-1 apolipoprotein A-1 
apo B apolipoprotein B 
ARB angiotensin receptor blocker 
bid twice a day 
BMI body mass index 
BP blood pressure 
 xxi
bw body weight 
CAD coronary artery disease 
CARE Cholesterol and Recurrent Events 
CCB calcium channel blocker 
CDC Centers for Disease Control and Prevention 
CETP  cholesteryl ester transfer protein 
CHD coronary heart disease 
CHF congestive heart failure 
CI confidence intervals 
CV coefficient of variation 
CVD cardiovascular disease 
DCCB Dihydropyridine calcium channel blocker 
DCCT Diabetes Control and Complications Trial 
DIGAMI Diabetes and Insulin-Glucose Infusion in Acute Myocardial 
Infarction 
ECG electrocardiogram 
EDTA ethylene diamine tetrachloroacetic acid 
ESRD end-stage renal disease 
FBG fasting blood glucose 
FDA Food and Drug Administration 
FFA free fatty acid 
FPG fasting plasma glucose 
FSG fasting serum glucose 
g gram 
GDM gestational diabetes mellitus 
 xxii
GFR glomerular filtration rate 
HDL high density lipoproteins 
HDLC HDL cholesterol 
HHS Helsinki Heart Study 
HMG CoA 3-hydroxy-3-methylglutaryl coenzyme A 
HOPE Heart Outcomes Prevention Evaluation 
hr hour  
HUSM Hospital Universiti Sains Malaysia 
IDDM insulin dependent diabetes mellitus 
IDF International Diabetes Federation 
IDL intermediate density lipoproteins 
IDLC intermediate density lipoprotein cholesterol 
IFG impaired fasting glucose 
IGT impaired glucose tolerance 
IPG impaired plasma glucose 
JNC Joint National Committee 
JNC V Fifth Joint National Committee on Hypertension 
JNC VI Sixth Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 
JODM juvenile-onset diabetes mellitus 
kcal kilo calorie 
kg kilo gram 
LCAS Lipoprotein and Coronary Atherosclerosis Study 
LDL low density lipoprotein 
LDLC LDL cholesterol 
 xxiii
LIPID Long-Term Intervention with Pravastatin in Ischaemic Disease 
Lp(a) lipoprotein(a) 
LPL lipoprotein lipase 
MBG mean blood glucose 
mg/dl milli gram per deciliter 
MI myocardial infarction 
MICRO-HOPE Microalbuminuria, Cardiovascular and Renal Outcomes in 
HOPE 
min minute  
mm Hg milli metre of mercury 
mmol/L milli mol per liter 
MNT medical nutrition therapy 
MODY maturity-onset diabetes of the young 
MRI magnetic resonance imaging 
NCEP National Cholesterol Education Program 
NCEP ATP II NCEP, Adult Treatment Panel II 
NCEP ATP III NCEP, Adult Treatment Panel III 
NDCCB non-DCCB 
NDDG National Diabetes Data Group 
NHANES National Health and Nutrition Examination Survey 
NHANES III Third National Health and Nutrition Examination Survey 
NIDDM Non insulin dependent diabetes mellitus 
NPDR nonproliferative diabetic retinopathy 
ODC Outpatient Diabetes Clinic 
OGTT oral glucose tolerance test 
 xxiv
 xxv
OHA oral hypoglycemic agent 
OR odds ratio 
PCOS  polycystic ovarian syndrome 
PDR proliferative diabetic retinopathy 
PG plasma glucose 
PVD peripheral vascular disease 
SD standard deviation 
SDLDL  Small, dense LDL 
SENDCAP the St. Mary ’s, Ealing, Northwick Park Diabetes Cardiovascular 
Disease Prevention (SENDCAP) Study 
SI Système International 
SMBG self-monitoring of blood glucose 
SPSS Statistical Package for Social Sciences 
TC total cholesterol 
TG triglycerides 
UAER urinary albumin excretion rate 
UKPDS United Kingdom Prospective Diabetes Study 
VA-HIT Veterans Affairs–HDL Intervention Trial, or Veteran’s 
Administration HDL Intervention Trial 
VLDLC VLDL cholesterol 
WESDR Wisconsin Epidemiologic Study of Diabetic Retinopathy 
WHO World Health Organization 
WHR waist-to-hip circumference ratio 
WOSCOPS  West of Scotland Coronary Prevention Study 
 
  
 
ABSTRACT 
 
 
This cross-sectional study was undertaken on 211 type 2 diabetic patients at the 
Outpatients Diabetes Clinic, HUSM Kubang Kerian, Kelantan between the year 2001 – 
2002.  The study was conducted to determine whether the clinical targets for the control 
of diabetes can be met in the context of routine endocrinology practice, and also to 
define the prevalence of dyslipidaemia, its correlation with glycaemic control and 
contributing factors.  Patients’ medical history as well as their family history were 
obtained using data collection form and physical examination was performed.  Samples 
of patients’ venous blood during fasting were taken and analysed for plasma glucose, 
glycated haemoglobin and lipid profile. 
Of the total 211 patients, only 4.3 % were on diet, 37 % of them were on mono 
therapy while 58.8% were on combination of therapies.  There were 46 % patients on 
lipid-lowering therapy and 54 % on antihypertensive therapy.  Analysis showed that 
many patients had comorbidities or complications.  A large number of them had poor 
glycaemic control (72.5 %).  Systolic and diastolic blood pressures of 75.4 % and 84.8 
% subjects were ≥ 130 and ≥ 80 mmHg, respectively. BMI values of 66.4 % of the 
patients were outside the clinical target (BMI ≥ 25 in male and ≥ 24 kg/m2 in female).  
The lipid profile showed that 96.2 % patients had at least one lipid value outside clinical 
target level.  In this study, 70.14 % of the patients had total cholesterol ≥ 5.2 mmol/L, 
87.2 % had LDL cholesterol ≥ 2.6 mmol/L, 57.4 % had HDL cholesterol less than the 
 xxvi
 xxvii
normal range, ≤ 1.15 mmol/L in men and ≤ 1.4 mmol/L in women, while 45.5 % had 
triglycerides ≥ 1.71 mmol/L.  The most common dyslipidaemic patterns were mixed 
hyperlipidaemia (36.8 %), followed by hypercholesterolaemia (34.2%) and 
hypertriglyceridaemia (5.3 %).  Complications of diabetes were observed in 47.9 % of 
the total number of patients. 
There were three variables that had significant effects on glycaemic control and 
they are ethnicity, age and duration of diabetes.  Younger Malay subjects (< 50 years 
old) had significantly the highest mean percent A1C.  Patients who were recently 
diagnosed (duration of diabetes < 5 years) had the best glycaemic control.  Variables 
that had significant effects on BMI were age, duration of diabetes, glycaemic control 
and gender.  Young female and newly diagnosed subjects with good glycaemic control 
(A1C < 7 %) were found to have higher BMI values.  As for the patients’ systolic blood 
pressure, only two factors, namely age and duration diabetes, were found to have 
significant effects.  Aged subjects with a long duration of diabetes were more 
hypertensive.  Based on the study conducted, results showed that glycaemic control and 
ethnicity were significantly important determinants of elevated total cholesterol, LDL 
cholesterol and triglycerides levels. Gender and BMI were identified to be significantly 
important determinants of elevated total cholesterol and triglycerides, respectively. 
 
The overall clinical targets were suboptimal.  The prevalence of hyperlipidaemia 
was high, particularly hypercholesterolaemia.  It is imperative that better treatment 
strategies and methods be adopted to enhance diabetes control and reduce long-term 
complications of the disease. 
 
  
 
ABSTRAK 
 
Faktor faktor yang memberi kesan kepada pengawalan Kawalan diabetes dan 
dislipidemia di kalangan pesakit diabetes jenis 2 di Hospital Universiti Sains 
Malaysia 
 
 Kajian keratan-lintang ini telah dijalankan terhadap 211 orang pesakit 
diabetes jenis 2 di Klinik Pesakit Luar, HUSM Kubang Kerian, Kelantan di antara tahun 
2001 – 2002.  Kajian ini bertujuan menentukan sama ada sasaran klinikal bagi 
mengawal penyakit diabetes dapat dicapai dalam konteks amalan rutin endokrinologi.  
Selain itu, kajian ini juga bertujuan mengenal pasti faktor-faktor yang mendorong 
kepada berlakunya dislipidemia serta perkaitannya antara kawalan tahap glukosa dalam 
darah.  Pemeriksaan fizikal dilakukan terhadap pesakit sementara butir-butir berkenaan 
dengan kesihatan dan latar belakang pesakit dan keluarga mereka diperolehi dengan 
cara mengedarkan borang soal selidik.  Sampel darah vena pesakit yang dalam keadaan 
berpuasa telah diambil dan dianalisis untuk menentukan tahap glukosa plasma darah, 
hemoglobin A1C dan profil lipid. 
 
Hanya 4.3 % daripada keseluruhan 211 orang pesakit mengikut diet pemakanan 
yang disyorkan, 37 % daripada mereka mengikuti satu bentuk terapi sementara 58.8 % 
mengikuti gabungan lebih daripada satu bentuk terapi.  Seramai 46 % daripada pesakit 
ini mengikuti terapi untuk menurunkan tahap lipid dan 54 % pula mengikuti terapi anti-
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hipertensif.  Analisis menunjukkan bahawa kebanyakan pesakit mengalami komplikasi 
diabetes.  Sebahagian besar daripada mereka ini tidak mempunyai kawalan glukosa 
dalam darah yang baik (72.5 %).  Seramai 75.4 % daripada pesakit menunjukkan bacaan 
tekanan darah sistolik ≥ 130 mmHg dan 84.8 % menunjukkan bacaan tekanan darah 
diastolik ≥ 80 mmHg.  Nilai BMI bagi 66.4 % daripada pesakit berada di luar sasaran 
klinikal (BMI ≥ 25 bagi pesakit lelaki dan ≥ 24 kg/m2 bagi pesakit wanita).  Profil lipid 
menunjukkan 96.2 % daripada jumlah pesakit mempunyai sekurang-kurangnya satu 
nilai di luar daripada tahap sasaran klinikal.  Dalam kajian ini, 70.14 % daripada jumlah 
pesakit mempunyai tahap kolesterol total  sebanyak ≥ 5.2 mmol/L dengan 87.2 % 
mempunyai tahap kolesterol LDL sebanyak ≥ 2.6 mmol/L dan 57.4 % pesakit 
mempunyai tahap kolesterol HDL kurang dari tahap normal, iaitu ≤ 1.15 mmol/L bagi 
lelaki dan ≤ 1.4 mmol/L bagi wanita sementara tahap trigliserida bagi 45.5 % daripada 
mereka berada pada ≥ 1.71 mmol/L.  Jenis-jenis dislipidemia yang lazim didapati adalah 
seperti hiperlipidemia (36.8 %), diikuti dengan hiperkolesterolemia (34.2 %) dan 
hipertrigliseridemia (5.3 %).  Terdapat 47.9 % daripada jumlah pesakit didapati 
mengalami komplikasi diabetes. 
 
Terdapat tiga pemboleh ubah yang mempunyai kesan yang signifikan terhadap 
kawalan glukosa dalam darah iaitu faktor etnik, umur dan jangka masa pesakit 
mengidap diabetes.  Pesakit Melayu yang lebih muda (< 50 tahun) mempunyai min 
peratus hemoglobin A1C yang paling tinggi.  Pesakit yang baru saja dikenal pasti 
mengidap diabetes (jangka masa < 5 tahun) didapati mempunyai kawalan glukosa 
dalam darah yang lebih baik.  Sementara itu, pemboleh ubah yang mempunyai kesan 
yang signifikan terhadap BMI pula ialah faktor umur, jangka masa pesakit mengidap 
diabetes, kawalan glukosa dalam darah dan jantina.  Pesakit wanita yang lebih muda dan 
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baru disahkan mengidap diabetes yang mempunyai kawalan glukosa dalam darah yang 
baik (tahap hemoglobin A1c [A1C] < 7 %) didapati mempunyai nilai BMI yang lebih 
tinggi.  Faktor umur dan jangka masa pesakit mengidap diabetes juga didapati memberi 
kesan yang signifikan terhadap tekanan darah sistolik pesakit.  Pesakit yang lebih tua 
dan mempunyai jangka masa mengidap diabetes yang lebih lama didapati mempunyai 
tekanan darah sistolik yang lebih tinggi.  Berdasarkan kajian yang dijalankan, keputusan 
menunjukkan bahawa kawalan glukosa dalam darah dan etnik merupakan dua faktor 
penting yang mendorong kepada peningkatan tahap kolesterol total, kolesterol LDL dan 
trigliserida yang signifikan. Jantina dikenal pasti sebagai faktor penting yang 
mendorong kepada peningkatan tahap kolesterol total manakala BMI mempengaruhi 
trigliserida. 
 
Kesimpulannya, sasaran klinikal secara keseluruhannya tidak dapat dicapai 
secara optimum.  Hiperlipidemia khususnya hiperkolesterolemia, masih berada pada 
tahap yang tinggi.  Oleh yang demikian, strategi serta kaedah rawatan yang lebih baik 
seharusnya dilaksana bagi meningkatkan tahap kawalan diabetes dan mengurangkan 
komplikasi penyakit ini dari segi jangka panjang.  
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INTRODUCTION 
 
 
1.1 Prevalence of type 2 diabetes  
Type 2 diabetes is the most prevalent form of diabetes, which appears later in 
life, and it is due to the combination of insulin resistance (impairment in insulin-
mediated glucose disposal) and defective secretion of insulin by pancreatic β-cells 
(Grundy et. al, 1999). Diabetes has become one of the most common chronic diseases 
all over the world. Using American Diabetes Association (ADA) criteria, the Third 
National Health and Nutrition Examination Survey, 1988 – 1994 (NHANES III) data 
indicate that diabetes (diagnosed and undiagnosed combined) affects 7.8 % of adults > 
20 years of age in the U.S., with rates reaching 18.8 % at > 60 years of age (Harris et. 
al, 1998). In Latin America, the prevalence of type 2 diabetes is highest among Pima 
Indians, followed by Hispanics, blacks, and then whites (Ismail & Gill, 1999). The 
prevalence of diabetes mellitus among Orang Asli was 0.3 % and among Malays was 
4.7 % (Ali et. al, 1993). Ethnic group, age (≥ 40 years), dietary intake, obesity, and lack 
of physical activity were associated with higher prevalence of diabetes (Ali et. al, 1993; 
Choi & Shi, 2001). The prevalence of diabetes mellitus and impaired glucose tolerance 
were 10.5 % and 16.5 % in Kelantan state of north-east Malaysia (Mafauzy et. al, 
1999). The high prevalence of undiagnosed diabetes and the proportion of cases with 
evidence of complications at diagnosis undoubtedly create a strong imperative for 
screening. Between 35 – 50 % cases of diabetes are undiagnosed at any one time. The 
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prevalence of new cases of diabetes in United Kingdom were 0.2 % (0 % to 1.4 %) and 
2.8 % (1.6 % to 4.7 %) in patients whose sole risk factor was age over 45 and in patients 
aged over 45 with one or more additional risk factors for diabetes, respectively 
(Lawrence et. al, 2001). Up to 25 % of people with diabetes have evidence of 
microvascular complications at diagnosis, and extrapolation of the association between 
the prevalence of retinopathy and the duration of disease suggests that the true onset of 
diabetes occurs several years before it is recognized clinically (Wareham & Griffin, 
2001).  There are currently 3.5 million people with type 1 diabetes and 119.2 million 
with type 2 diabetes worldwide, and the number is expected to increase to 5.3 and 212.9 
million, respectively in the year 2011 (Bloomgarden, 1998).  There have been increases 
in the prevalence of diabetes from 4 to 8 % in Singapore, from 8 to 16 % in Papua New 
Guinea, and from 2 to 5 % in Hong Kong (Bloomgarden, 1998). The American 
Diabetes Association has proposed screening of all people aged over 45 years by 
measuring fasting blood glucose every three years, in addition to screening patients 
from high-risk ethnic groups and younger patients with hypertension, obesity, a family 
history of diabetes in a first degree relative, or a family history of gestational diabetes 
(The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997; 
ADA, 1998c). Criteria for testing for diabetes in asymptomatic, undiagnosed adults are 
listed in Table 1.1. The recommended screening test for nonpregnant adults is the 
fasting plasma glucose (ADA, 2002f). 
The incidence of type 2 diabetes is increasing in the pediatric population, and 
presents a serious public health problem. The full effect of this epidemic will be felt as 
these children become adults and develop the long-term complications of diabetes 
(Rosenbloom et. al, 1999). Until recently, immune-mediated type 1 diabetes was the 
only type of diabetes and was the most common and increasingly prevalent chronic 
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diseases in children. Only 1 – 2 % of children were considered to have type 2 diabetes 
or other rare forms of diabetes. Recent reports indicate that 8 – 45 % of children with 
newly diagnosed diabetes have nonimmune-mediated diabetes (ADA, 2000b). In US the 
mean age of children at diagnosis of type 2 diabetes is between 12 and 14 years, 
corresponding with puberty. The disease affects girls more than boys, predominantly 
people of non-European origin, and is associated with obesity, physical inactivity, a 
family history of type 2 diabetes, exposure to diabetes in utero, and signs of insulin 
resistance (Fagot-Campagna & Narayan, 2001). Criteria for testing for type 2 diabetes 
in children are listed in Table 1.2. 
 
Table 1.1 Criteria for testing for diabetes in asymptomatic adults 
 
Criteria for testing for diabetes in asymptomatic adult individuals 
1. Testing for diabetes should be considered in all individuals at age 45 years and 
above and, if normal, it should be repeated at 3-year intervals. 
2. Testing should be considered at a younger age or be carried out more frequently 
in individuals who 
• are overweight (BMI > 25 kg/m2) 
• have a first-degree relative with diabetes 
• are members of a high-risk ethnic population (e.g., African-American, Latino, 
Native American, Asian-American, Pacific Islander) 
• have delivered a baby weighing > 9 lb or have been diagnosed with GDM 
• are hypertensive ( >140/90 mmHg) 
• have an HDL cholesterol level < 35 mg/dl (0.90 mmol/l) and/or a triglycerides 
level > 250 mg/dl (2.82 mmol/l) 
• on previous testing, had IGT or IFG 
• have other clinical conditions associated with insulin resistance (e.g. PCOS or 
acanthosis nigricans) 
(ADA, 2002f). 
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Table 1.2 Criteria for testing for type 2 diabetes in children 
Testing for type 2 diabetes in children  
• Criteria* 
Overweight (BMI > 85th percentile for age and sex, weight for height > 85th percentile, 
or weight > 120% of ideal for height) Plus, Any two of the following risk factors:  
1. Family history of type 2 diabetes in first- or second-degree relative         
2. Race/ethnicity (Native American, African-American, Latino, Asian  
American, Pacific Islander) 
3. Signs of insulin resistance or conditions associated with insulin resistance 
(acanthosis nigricans, hypertension, dyslipidaemia, or PCOS) 
• Age of initiation: age 10 years or at onset of puberty, if puberty occurs at a 
younger age 
• Frequency: every 2 years 
• Test: FPG preferred 
*Clinical judgment should be used to test for diabetes in high-risk patients who do not 
meet these criteria (ADA, 2002f). 
 
Diabetes mellitus is a major risk factor for morbidity and mortality due to 
coronary heart disease (CHD), cerebrovascular disease, and peripheral vascular disease. 
Diabetes increases the prevalence of these complications about two to fourfold (ADA, 
1989). Metabolic control and duration of type 2 diabetes are important predictors of 
coronary heart disease (ischemic heart disease) in elderly subjects, particularly in 
women (Kuusisto et. al, 1994). High fasting insulin concentrations are independent 
predictor of coronary heart disease (ischemic heart disease) in men (Despres et. al, 
1996).  Risk factors for these complications in diabetic patients are the high prevalence 
of hypertension and lipid abnormalities. Smoking is another risk factor. Other 
associated risk factors for macrovascular complications are obesity, impaired glucose 
tolerance, hyperglycaemia, hyperinsulinaemia, microalbuminuria, elevated fibrinogen 
levels, altered platelet function, and qualitative lipoprotein abnormalities (ADA, 1989).  
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 1.2 Diagnosis of diabetes mellitus  
 
Symptoms of diabetes include polydipsia (increased thirst), polyuria (increased 
urine volume), recurrent infections, and unexplained weight loss. In severe cases, 
drowsiness, coma and high levels of glycosuria are usually present. Diabetes can be 
diagnosed in three ways according to The Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus (2002) (Alberti & Zimmet, 1998; The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997; 2002). 
1. Symptoms of diabetes plus casual plasma glucose ≥ 11.1 mmol/L (200 mg/dl) or  
2. FPG ≥ 7.0 mmol/L (126 mg/dl) or  
3. 2-h PG ≥ 11.1 mmol/L (200 mg/dl) during an oral glucose tolerance test 
(OGTT). 
(i) In persons with symptom of diabetes:  
Symptoms of diabetes plus casual plasma glucose ≥ 11.1 mmol/L (200 mg/dl) or FPG ≥ 
7.0 mmol/L (126 mg/dl) or 2-h PG ≥ 11.1 mmol/L (200 mg/dl) during an oral glucose 
tolerance test (OGTT). 
(ii) For asymptomatic person, Abnormal tests on two occasions.  
The diagnosis needs to be confirmed by repeating the test on a different day. At 
least one additional plasma glucose test result with a value in the diabetic range is 
essential, either fasting, from a random (casual) sample, or from the oral glucose 
tolerance test. A single blood glucose estimation in excess of the diagnostic values 
indicated in Figure 1.1. However, the oral glucose tolerance test is discouraged for 
routine clinical use. In epidemiological studies, one fasting plasma glucose 
measurement will suffice. The World Health Organization (WHO) reserved the use of 
fasting plasma glucose or 2-hour plasma glucose measurements for epidemiological 
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purposes and suggested that ideally, both values should be used (Alberti & Zimmet, 
1998; The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 
1997; 2002). Diagnostic interpretations of the fasting and 2-h post-load concentrations 
in non-pregnant subjects are listed in Table 1.3. 
 
 
 
 
 
 
Figure 1.1 Unstandardized (casual, random) blood glucose values in the diagnosis of 
diabetes mellitus 
Values are in mmol/L (mg/dl).  
Taken from the WHO Consultation Report (1999). 
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Table 1.3 Fasting and 2-h post-load glucose values for diagnosis of diabetes mellitus 
and other categories of hyperglycaemia 
 
Category  
 
Sampling 
time  
Glucose concentration, mmol/L (mg/dl) 
Whole blood Plasma 
Venous Capillary Venous Capillary 
Diabetes 
Mellitus 
 
Fasting * 
≥ 6.1 
(110) 
≥ 6.1  
(110) 
≥ 7  
(126) 
≥ 7 
(126) 
2-h post 
glucose 
load** 
≥ 10 
(180) 
≥ 11.1 
(200) 
≥ 11.1 
(200) 
≥ 12.2 
(220) 
Impaired 
Glucose 
Tolerance 
(IGT) 
 
Fasting * 
< 6.1  
(110) 
< 6.1  
(110) 
< 7 
(126) 
< 7 
(126) 
2-h post 
glucose 
load** 
≥ 6.7- <10  
(120 - 180) 
≥ 7.8 - < 11.1 
(140 - 200) 
≥ 7.8 - < 11.1  
(140 - 200) 
≥ 8.9-< 12.2 
(160 - 220) 
Impaired 
Fasting 
Glycaemia 
(IFG) 
 
Fasting* 
≥ 5.6 - < 6.1 
(100 - 110) 
≥ 5.6 - < 6.1  
(100 - 110) 
≥ 6.1 - < 7 
(110 - 126) 
≥ 6.1 - < 7 
(110 - 126) 
2-h post 
glucose 
load** 
< 6.7 
(120) 
< 7.8 
(140) 
< 7.8 
(140) 
< 8.9 
(160) 
Taken from the WHO Consultation Report (1999). 
* 10 – 12 hours 
** 75 gr oral glucose load 
Values are for non-pregnant subjects. 
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1.3 Classification of diabetes mellitus  
With a better understanding of the pathophysiology and regulation of glucose 
metabolism, new classifications of diabetes based on aetiologies and clinical staging 
(Figure 1.2) have been recommended by the World Health Organization (Alberti & 
Zimmet, 1998; WHO Consultation, 1999) and the American Diabetes Association (The 
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997; 
2002). Both the reports of the American Diabetes Association and the World Health 
Organization recommend altering the classification to define four main subtypes of 
diabetes.  
            
1. Type 1 diabetes (previously called insulin-dependent diabetes mellitus [IDDM] or 
juvenile-onset diabetes mellitus [JODM]) represents clinically about 5 percent of all 
persons with diagnosed diabetes. Its clinical onset is typically at ages under 30 years. It 
is an autoimmune or idiopathic destructive disease in beta (insulin-producing) cells of 
the pancreas in genetically susceptible individuals, which leads to absolute insulin 
deficiency. The clinical onset of Type 1 diabetes may be more gradual after age 30. 
Insulin therapy is always required for both life and diabetes control.  
 
2. Type 2 diabetes (previously called non-insulin-dependent diabetes mellitus 
[NIDDM] or adult-onset diabetes [AODM]), which may originate from insulin 
resistance and relative insulin deficiency or from a secretory defect. Type 2 diabetes is 
the most common form of diabetes in the world, especially in minority communities and 
the elderly. Approximately 95 % of all persons with diagnosed diabetes and 100 % of 
undiagnosed diabetes have type 2 diabetes.  
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Type of diabetes 
mellitus 
Normoglycaemia Hyperglycaemia 
 Diabetes mellitus 
 Normal glucose 
tolerance 
IGT* 
and/or 
IFG † 
Not 
requiring 
insulin 
Requiring 
insulin for 
control 
Requiring 
insulin for 
survival 
 
Type 1 
Autoimmune 
Idiopathic 
 
     
Type 2 
Predominantly insulin 
resistance 
Predominantly insulin 
secretory defects 
     
 
 
Other specific types ‡ 
 
 
     
 
 
Gestational diabetes ‡ 
 
 
     
 
Figure 1.2 Disorders of glycaemia: aetiological types and clinical stages 
 
* IGT impaired glucose tolerance, † IFG impaired fasting glycaemia, ‡ In rare 
instances, patients in these categories (e.g. type 1 diabetes mellitus during pregnancy) 
may require insulin for survival 
Taken from The Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus (2002). 
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3. Other specific types: it covers a wide range of specific types of diabetes including 
the various genetic defects of beta cell function, genetic defects in insulin action, 
diseases of the exocrine pancreas and medication use.  
(a) Genetic defects of β-cell function (e.g. maturity onset diabetes of 
youth types 1 – 6) 
(b) Genetic defects in insulin action (e.g. type A insulin resistance) 
(c) Diseases of the exocrine pancreas (e.g. pancreatitis, 
haemochromatosis) 
(d) Endocrinopathies (e.g. acromegaly, Cushing’s syndrome) 
(e) Drug or chemical induced (e.g. thiazides, glucocorticoids) 
(f) Infections (e.g. congenital rubella) 
(g) Uncommon forms of immune-mediated diabetes (e.g. ‘stiff man’ 
syndrome) 
(h) Other genetic syndromes sometimes associated with diabetes (e.g. 
Down’s syndrome, Lawrence-Moon-Biedel syndrome) 
  
 
4. Gestational Diabetes Mellitus (GDM): it is the recognition of hyperglycemia during 
pregnancy in an individual not previously known to have diabetes. Approximately 3 
percent of all pregnancies are associated with Gestational Diabetes Mellitus. Gestational 
Diabetes Mellitus identifies health risks to the fetus/newborn and future diabetes in the 
mother. 
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1.4 Hyperglycemia 
Type 2 diabetes is a progressive disease associated with numerous serious 
complications that develop over time. Patients with type 2 diabetes are at increased risk 
for cardiovascular disease. These complications are directly and strongly related to 
hyperglycemia (Stratton et. al, 2000). Hyperglycemia affects biochemical parameters 
and influences the progression of coronary heart disease and mortality rates in diabetic 
patients. Aggressive treatment to control hyperglycemia is much more effective in 
reducing the number of complications than standard treatment (Van der does et. al, 
1998; Herman, 1999). In the Paris Prospective Study, in the upper levels of glucose 
distributions, the risk of death progressively increased with increasing fasting and 2-h 
glucose concentrations. There were no clear thresholds for fasting or 2-h glucose 
concentrations above which mortality sharply increased (Balkau et. al, 1999). 
 
1.4.1 Fasting Plasma Glucose 
Impaired fasting plasma glucose or impaired glucose tolerance is the first 
abnormality in plasma glucose seen in patients with insulin resistance (The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997). Many 
prospective studies (Rewers et. al, 1992; Haffner, 1997; Goldberg et. al, 1998; Coutinho 
et. al, 1999) show that impaired fasting plasma glucose or impaired glucose tolerance is 
a risk factor for cardiovascular diseases. The risk of developing cardiovascular diseases 
is greater in people with both impaired glucose tolerance and impaired fasting plasma 
glucose (Lim et. al, 2000). The degree of independence as a risk factor, however, is 
uncertain, because impaired fasting plasma glucose commonly coexists with other 
components of the metabolic syndrome (Haffner et. al, 1990). A patient with impaired 
fasting plasma glucose or impaired glucose tolerance are at risk for both cardiovascular 
diseases and type 2 diabetes (Rewers et. al, 1992). Once categorical hyperglycemia or 
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diabetes develops, it counts as an independent risk factor for cardiovascular disease 
(Wilson, 1998). There is a direct relationship between the degree of plasma glucose 
control and the risk of microvascular complications of both type 1 (Diabetes Control 
and Complications Trial [DCCT] Research Group, 1993) and type 2 (U.K. Prospective 
Diabetes Study [UKPDS] Group, 1998e) diabetes. Type 1 diabetic patients with lower 
average plasma glucose concentrations had a significantly lower incidence of 
microvascular complications, but reduction in the risk of macrovascular complication 
was not significant (DCCT Research Group, 1993), and 34 % reduction in 
hypercholesterolemia was observed with intensive insulin therapy. Similar results were 
observed in type 2 diabetic patients (UKPDS Group, 1998e). Poor prognosis is directly 
related to higher glucose concentrations. For example, the 10-year survival was reduced 
if fasting plasma glucose was ≥ 7.8 mmol/L. The risk of death was significantly 
increased for patients with fasting plasma glucose ≥ 7.8 mmol/L. Type 2 diabetic 
patients with fasting plasma glucose ≥ 7.8 mmol/L had increased cardiovascular 
mortality and a moderately increased in FPG was a risk factor for myocardial infarction 
(Andersson & Svardsudd, 1995). 
 
1.4.2 Glycated hemoglobin 
Glycated hemoglobin is formed from the slow, non-enzymatic reaction between 
glucose and hemoglobin  (Bun, 1981). For hemoglobin, the rate of synthesis of glycated 
hemoglobin is principally related to the concentration of plasma glucose.  Measurement 
of glycated proteins, primarily glycated hemoglobin, is widely used for routine 
monitoring of long-term glycaemic status in patients with diabetes mellitus.  Glycated 
hemoglobin is a clinically useful index of mean glycaemia during the preceding 120 
days, the average life span of erythrocytes (Bunn, 1981; Jovanovic & Peterson, 1981; 
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Nathan et. al, 1984; Cefalu et. al, 1994; Goldstein et. al, 1995). In most studies glycated 
hemoglobin was used to evaluate glycaemic control, rather than glucose concentration. 
Moreover, most clinicians use the American Diabetes Association recommendations, 
which define a target glycated hemoglobin concentration as the goal for optimum 
glycaemic control. The predicted incidence of nonproliferative (background) diabetic 
retinopathy (NPDR), proliferative diabetic retinopathy, macular edema and blindness 
were reduced by 66 %, 94 %, 71 % and 72 % in comprehensive care compared with 
standard care. Comprehensive care reduced nephropathy outcomes by 39 % 
(microalbuminuria) and 87 % (proteinuria, ESRD) and reduced neuropathy outcomes by 
68 % (symptomatic distal polyneuropathy) and 67 % (lower extremity 
amputation)(Eastman et. al, 1997). Glycated hemoglobin concentration seems to explain 
most of the excess mortality risk of diabetes in men and to be a continuous risk factor 
through the whole population distribution (Khaw et. al, 2001). The incidences of 
mortality attributed to coronary heart disease and all coronary heart disease events 
increased significantly in patients with glycated hemoglobin concentrations in the 
highest tertile (> 7.9 %) compared with patients with glycated hemoglobin 
concentrations lower than 6 % (Kuusisto et. al, 1994). Each 1 % reduction in glycated 
hemoglobin was associated with reductions in risk of ≥ 45 % for the progression of 
diabetic retinopathy (DCCT Research Group, 1995), 21 % for any end point related to 
diabetes, 21 % for deaths related to diabetes, 14 % for myocardial infarction, and 37 % 
for microvascular complications (Stratton et. al, 2000).  
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 1.5 Diabetic dyslipidaemia 
 
The term hyperlipidaemia refers to an increase in concentration of one or more 
plasma or serum lipids, usually cholesterol and triglycerides and the term dyslipidaemia 
is used for either an increase or decrease in concentration of one or more plasma or 
serum lipids. Cholesterol and triglycerides are transported in the blood in the form of 
lipoproteins. Plasma total cholesterol in human is distributed among three major 
lipoprotein classes: very low-density lipoproteins (VLDL), low-density lipoproteins 
(LDL) and high-density lipoproteins (HDL). Smaller amounts of cholesterol are also 
contained into minor lipoprotein classes: intermediate density lipoproteins (IDL) and 
lipoprotein (a) [Lp (a)]. LDL carry most of the circulating cholesterol (60 – 70 % of 
total cholesterol). HDL contain 20 – 30 % of the total cholesterol and they play a major 
role in reverse cholesterol transport. The dietary triglycerides are transported in 
chylomicra from its intestinal site of absorption into the systemic circulation. The 
endogenously synthesized triglycerides are transported in VLDL. The desirable lipid 
profile (total, HDL, LDL cholesterol and triglycerides) is as follow: Total cholesterol < 
5.2 mmol/L or triglycerides < 1.71 mmol/L, low-density lipoprotein (LDL) < 2.6 
mmol/L and high-density lipoprotein (HDL) ≥ 1.15 mmol/L. A subject is considered 
dyslipidaemic when one of the above criteria is fulfilled (The National Cholesterol 
Education Program, 2001; ADA, 2002d). The study of lipid profile is necessary in 
diagnosis and treatment of dyslipidaemia.  
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The pathophysiology of underlying diabetic dyslipidemia is closely linked to 
insulin resistance, which in turn leads to increased release of fatty acids from adipose 
tissue (Nikkila & Kekki, 1973; Frayne et. al, 1996). Increased plasma levels of fatty 
acids increase production of VLDL, TG, and cholesterol by the liver (Nikkila & Kekki, 
1973; Frayne et. al, 1996).). Increased plasma TG levels are then the “driving force” for 
low HDLC and abnormal, small dense LDL (Reaven et. al, 1993; Griffin et. al, 1994; 
Tan et. al, 1995).  The pathophysiologic basis for diabetic dyslipidemia and its relation 
to insulin resistance is presented in Figure 1.3.  In the first, we see that insulin-resistant 
fat cells undergo greater breakdown of their stored triglycerides and greater release of 
free fatty acids into the circulation (Nikkila & Kekki, 1973; Frayne et. al, 1996).  This is 
a common abnormality seen in both obese and nonobese insulin-resistant subjects and 
those with type 2 diabetes (Goldberg, 2001).  Increased fatty acids in the plasma leads to 
increase fatty acid uptake by the liver. The liver takes those fatty acids and synthesizes 
them into triglycerides (Nikkila & Kekki, 1973; Frayne et. al, 1996). The presence of 
increased triglycerides stimulates the assembly and secretion of the apolipoprotein (apo) 
B and very low density lipoprotein (Goldberg, 2001).  The result is an increased number 
of VLDL particles and increased level of triglycerides in the plasma, which leads to the 
rest of the diabetic dyslipidemic picture. In the presence of increased VLDL in the 
plasma and normal levels of activity of the plasma protein cholesteryl ester transfer 
protein (CETP), VLDL triglycerides can be exchanged for HDL cholesterol.  That is, a 
VLDL particle will give up a molecule of triglyceride, donating it to the HDL, in return 
for one of the cholesteryl ester molecules from HDL (Channon et. al, 1990; Bhatnagar 
et. al, 1992).  This leads to two outcomes:  a cholesterol-rich VLDL remnant particle 
that is atherogenic, and a triglyceride-rich cholesterol-depleted HDL particle.  The 
triglyceride-rich HDL particle can undergo further modification including hydrolysis of 
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its tryglyceride, probably by hepatic lipase, which leads to the dissociation of the 
structurally important protein apo A-I.  The free apo A-I in plasma is cleared more 
rapidly than apo A-I associated with HDL particles.   In this situation, HDL cholesterol 
is reduced, and the amount of circulating apo A-I and therefore the number of HDL 
particles is also reduced (Caslake et. al, 1992). A similar phenomena leading to small, 
dense LDL.  Increased levels of VLDL triglyceride in the presence of CETP can 
promote the transfer of triglyceride into LDL in exchange for LDL cholesteryl ester 
(Channon et. al, 1990; Bhatnagar et. al, 1992).  The triglyceride-rich LDL can undergo 
hydrolysis by hepatic lipase or lipoprotein lipase, which leads to a small, dense, 
cholesterol-depleted—and, in general, lipid-depleted—LDL particle (Caslake et. al, 
1992). 
 
 
 
 
Figure 1. 3 The pathophysiologic basis for diabetic dyslipidemia and its relation to 
insulin resistance 
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Small, dense LDL appears to be more susceptible to oxidative modification 
(Chait et. al, 1993; Dejager et. al, 1993).  Because they are smaller, these particles 
appear to penetrate the endothelial layer of the arterial wall more easily.  The apo B 
molecule in small, dense LDL undergoes a conformational change that leads to 
decreased affinity for the LDL receptor, therefore allowing this LDL particle to remain 
in the circulation longer and be more liable to oxidative modification and uptake into 
the vessel wall.  Finally, in population studies and small clinical studies, small, dense 
LDL is associated with the insulin-resistance syndrome as well as with high 
triglycerides and low HDL cholesterol (Austin & Edwards, 1996). There are a number 
of reasons to consider hypertriglyceridemia as at least a marker of increased atherogenic 
potential.  First of all, hypertriglyceridemia is associated with the accumulation of 
chylomicron remnants, which we know can be atherogenic, and accumulation of VLDL 
remnants, which are also atherogenic.  As previously discussed, hypertriglyceridemia 
generates small, dense LDL and is the basis for low HDL in the general population.  
Hypertriglyceridemia is also associated with increased coagulability and decreased 
fibrinolysis, as shown by its association with increased levels of plasminogen activator 
inhibitor 1 (PAI-1) and factor VII and its activation of prothrombin to thrombin (Austin 
& Edwards, 1996). 
People with diabetes frequently have elevated levels of triglycerides, whereas 
HDL-cholesterol levels are lower than in people without the disease (Dean et. al, 1996). 
Poor glycaemic control worsens lipid abnormalities associated with type 2 diabetes 
(Dean et. al, 1996). In addition, diabetic nephropathy and obesity contribute to adverse 
changes in the plasma lipid pattern (Dean et. al, 1996). The central characteristic of 
dyslipidaemia in patients with type 2 diabetes is an elevated triglycerides level, 
particularly triglycerides-rich VLDL levels and decreased HDL cholesterol levels 
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(ADA, 2002d). In diabetic patients, the concentration of LDL cholesterol is usually not 
significantly different from that seen in non-diabetic individuals (ADA, 2002d). 
However, patients with type 2 diabetes typically have a preponderance of smaller, 
denser, oxidized LDL particles, which may increase atherogenicity (Lamarche et. al, 
1997; ADA, 2002d), even if the absolute concentration of LDL cholesterol is not 
elevated. This lipid triad, referred to as atherogenic dyslipidaemia, is usually present in 
patients with premature coronary artery disease. Atherogenic dyslipidaemia (diabetic 
dyslipidaemia) is characterized by 3 lipoprotein abnormalities: elevated very-low-
density lipoproteins (VLDL), small LDL particles, and low high-density-lipoprotein 
(HDL) cholesterol (the lipid triad). (Grundy, 1997; Grundy et. al, 1999). This shift in 
lipid levels increases the risk to develop coronary heart disease (Koskinen et. al, 1992; 
Manninen et. al, 1992; Gardner et. al, 1996). The presence of increased triglycerides 
and decreased HDL levels are the best predictor of cardiovascular disease in patients 
with type 2 diabetes (Laakso et. al, 1993). Most recently, results of the Strong Heart 
Study indicate that LDL cholesterol is an independent predictor of cardiovascular 
disease in patients with diabetes, along with age, albuminuria, fibrinogen, HDL 
cholesterol (inverse predictor), and percent body fat (inverse predictor) (Howard et. al, 
2000). Starting with LDL levels as low as 1.82 mmol/L (70 mg/dl), every 0.26 mml/L 
(10 mg/dl) increase in LDL cholesterol was associated with a 12 % increase in risk of 
cardiovascular disease. This finding is supported by results of prospective, long-term 
clinical trials in which reduction of LDL levels was associated with a significantly 
reduced risk of cardiovascular events in both diabetic and non-diabetic participants 
(Goldberg et. al, 1998). In an analysis from the Framingham Heart Study (Garg & 
Grundy, 1990), lipid levels in men and women with and without diabetes were 
compared to levels in the overall U.S. population.  For total cholesterol and LDL 
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cholesterol, there were no differences between normal and diabetic men or between 
normal and diabetic women.  However, the diabetic men and women had about twice 
the prevalence of low HDL cholesterol levels and about twice the prevalence of high 
triglyceride levels as did their nondiabetic counterparts. Results from the Strong Heart 
Study (Howard, 1998) help to explain why the Framingham data show relatively higher 
rates of CHD mortality in diabetic women than diabetic men.  Among women, HDL 
cholesterol was approximately 8 mg/dl lower in diabetics compared with nondiabetics, 
whereas among men, HDL cholesterol was about 4 mg/dl lower in diabetics compared 
with nondiabetics. A comparison of LDL particle size also indicates a relatively greater 
decrease with diabetes among women compared with men. In a comparison of diabetic 
men and women from the United Kingdom Prospective Diabetes Study (UKPDS, 1997) 
and normal healthy control subjects, total cholesterol levels did not differ between the 
diabetics and the control subjects.  For LDL cholesterol, there was also no difference 
among the men; however, women with type 2 diabetes in UKPDS had slightly but 
significantly higher LDL cholesterol levels than their normal counterparts.  The data are 
more striking, however, for both HDL cholesterol, which was lower in the diabetics for 
both genders, and for triglycerides, which were higher in the diabetic subjects than in 
the normal control subjects. 
About 97 % of adults with diabetes have one or more lipid abnormalities (Henry, 
2001). In the San Antonio Heart Study more than 40 % of diabetic patients were 
hyperlipidaemic and an additional 23 % had hypertriglyceridaemia and/or low level of 
HDL cholesterol (Stern et. al, 1989). High or borderline-high total cholesterol were 
observed in 70 % of the individuals with diagnosed diabetes, and 77 % of those with 
undiagnosed diabetes (Harris, 1991). Finnish investigators reported a 53 % prevalence 
of hypercholesterolemia (plasma cholesterol > 6.5 mmol/l) in a non-insulin-dependent 
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diabetes mellitus cohort, which was similar to the prevalence in the corresponding non-
diabetic population (Rönnemaa et. al, 1989). Despite the high and widespread 
prevalence of dyslipidaemia among people without and with diabetes, only 2.2 %  
(Primatesta & Poulter, 2000) of adults without diabetes and 32 % (Henry, 2001) of 
diabetic patients are receiving treatment with diet, exercise, or drugs to reduce lipid 
levels and less than one third of patients with established cardiovascular disease 
received such treatment. (Primatesta & Poulter, 2000). Furthermore, among those who 
are being treated, only 1 % have reached the ADA goal of LDL < 2.6 mmol/L (100 
mg/dl) (Henry, 2001). The prevalence and patterns of diabetic dyslipidaemia among 
type 2 diabetic patients in Malaysia is summarized in Table 1.4. 
 
Table 1.4 Prevalence of diabetic dyslipidaemia in Malaysia  
Mohamad et al., 1997 (70 type 2 diabetic patients) 
Hypercholeterolaemia (≥ 6.1 mmol/L)                                    80 %   
Hypertriglyceridaemia (≥ 2.7 mmol/L)                                   58 % 
Hyper LDL- choleterolaemia (≥ 4 mmol/L)                            68.5 % 
Low HDL-choleterolaemia (< 0.9 mmol/L)                            17.6 % 
Mafauzy et al., 1999 (diabetic) 
Hypercholeterolaemia (≥ 5.2mmol/L)                                      71.9 %   
Mixed hyperlipidaemia (TC ≥ 5.2 and TG ≥ 2.3)                     23 %  
Ismail et al., 2001 (type 2 diabetic patients) 
Hypercholeterolaemia (> 5.2mmol/L)                                      73.2 %   
Hypertriglyceridaemia (> 2.3 mmol/L)                                     27.3 % 
Hyper LDL- choleterolaemia (> 2.6 mmol/L)                           90.9 % 
Low HDL-choleterolaemia (< 1.15 mmol/L)                           52.6 % 
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 Type 2 diabetic patients have markedly increased risk of coronary heart disease 
than similarly dyslipidaemic non diabetic subjects (Koskinen et. al, 1992). Low HDL 
and HDL2 cholesterol, high VLDL cholesterol, and high total and VLDL triglycerides 
are powerful risk indicators for coronary heart disease events in patients with non-
insulin-dependent diabetes mellitus (Laakso et. al, 1993). LDL size is associated 
inversely and prospectively with the incidence of coronary artery disease (Gardner et. 
al, 1996). Serum triglycerides concentration has prognostic value, both for assessing 
coronary heart disease risk and in predicting the effect of Gemfibrozil treatment, 
especially when used in combination with HDL and LDL cholesterol (Manninen et. al, 
1992).  Cholesterol-lowering therapy will be beneficial for the majority of patients with 
coronary disease who have average cholesterol levels (Sacks et. al, 1996). The 
incidences of coronary heart disease mortality and all coronary heart disease events 
were significantly related to total cholesterol and total triglycerides. Furthermore, HDL 
cholesterol was significantly and inversely related to both coronary heart disease 
mortality and all coronary heart disease events (Lehto et. al, 1997). Baseline data from 
the United Kingdom Prospective Diabetes Study (UKPDS) showed that both decreased 
HDL and elevated LDL cholesterol predicted coronary heart disease (Turner et. al, 
1998). HDL cholesterol concentration is inversely correlated with risk of coronary heart 
disease and low HDL cholesterol concentration is a strong and important independent 
predictor of coronary heart disease. 
Drugs were developed that lowered circulating cholesterol concentrations and 
the drugs were tested in clinical trials. Results of these trials showed that lowering LDL 
cholesterol reduced the risk of morbid and mortal coronary events (Table1.5). Two 
major classes of lipid-lowering agents, the statins (3-hydroxy-3-methylglutaryl 
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coenzyme A [HMG CoA] reductase inhibitors) and fibrates (fibric acid derivatives), are 
available. Nicotinic acid, because of its deleterious effect on glucose tolerance, and bile 
acid binding resins, because of their triglycerides-elevating properties, are not first-
choice agents in patients with non-insulin-dependent diabetes mellitus (Tikkanen et. al, 
1998). Simvastatin had powerful LDL cholesterol and total cholesterol–lowering 
efficacy in both plasma lipid phenotypes and can be recommended for treatment of both 
types of hyperlipidaemia (combined  hyperlipidaemia and isolated 
hypercholesterolaemia) in non-insulin-dependent diabetes mellitus patients. 
Gemfibrozil, which had no effect on LDL cholesterol in combined hyperlipidaemia but 
effectively lowered triglycerides levels, can be used in patients with high triglycerides 
and normal or low LDL cholesterol levels (Tikkanen et. al, 1998).  
 
 
Table 1.5 Effect of Statin Therapy on CHD: Clinical Events Trials 
 
Trial Baseline 
LDLC‡ 
↓LDLC‡ LDLC ‡ 
Achieved 
Statin  
Event* Rate 
Placebo 
Event* Rate 
RRR
4S 188 35% 122 19.4% 28.0% 34% 
LIPID 150 25%† 112 12.3% 15.9% 24% 
CARE 139 32% 98 10.2% 13.2% 24% 
WOSCOPS 192 26% 159 5.3% 7.5% 29% 
AFCAPS 150 25% 115 3.5% 5.5% 37% 
*Nonfatal MI or CHD death in WOSCOPS, CARE, LIPID; nonfatal or fatal MI, 
unstable angina, or sudden cardiac death as first event in AFCAPS; nonfatal MI, 
coronary death, or resuscitated cardiac arrest in 4S.  
†vs. placebo, ‡ (mg/dl) 
 
 
 
 23
Reduction in recurrent coronary heart disease events in diabetic patients in the 
Scandinavian Simvastatin Survival Study (4S), (Scandinavian Simvastatin Survival 
Study Group, 1994; Pyorala et. al, 1997), the Cholesterol and Recurrent Events (CARE) 
trial, (Sacks et. al, 1996; Goldberg et. al, 1998) and the Long-Term Intervention with 
Pravastatin in Ischaemic Disease (LIPID)(The Long-Term Intervention with Pravastatin 
in Ischaemic Disease [LIPID] Study Group, 1998) clinical trials were associated with 
aggressive LDL-lowering therapy (Table 1.6). In the Scandinavian Simvastatin Survival 
Study (4S) trial, Simvastatin (HMG CoA reductase inhibitor or “statin”) significantly 
reduced coronary heart disease incidence and total mortality (borderline significantly) in 
diabetic subjects with high LDL cholesterol and with previous clinical coronary heart 
disease. In the Cholesterol and Recurrent Events (CARE) study (Sacks et. al, 1996), 
Pravastatin reduced coronary heart disease incidence significantly in diabetic subjects 
with average LDL cholesterol levels and with previous clinical coronary heart disease. 
Patients without previous MI were studied in the West of Scotland Coronary Prevention 
Study (WOSCOPS) (Shepherd et. al, 1995), which examined patients with severe 
hypercholesterolemia, and the Air Force/Texas Coronary Prevention Study 
(AFCAPS/TexCAPS) (Downs et. al, 1998), which studied patients with average 
cholesterol.  Trials showed that lipid lowering with a statin prevents clinical events, and 
with each study, the pool of patients proven to benefit was expanded.  In the Helsinki 
Heart Study (Koskinen et. al, 1992), Gemfibrozil (fibric acid derivative) was associated 
with a reduction in coronary heart disease in diabetic subjects without prior coronary 
heart disease (although this result was not statistically significant) (Table 1.7).  
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Table 1.6 Outcome of clinical events trials of statin in prevention of new coronary heart 
disease (CHD) events 
 
                                                    Effect of statin on CHD risk (%)   Level of significance 
Secondary prevention 
4S  
     All participants (N = 4444)                                 - 34                              P < 0.00001 
     Diabetes (n = 202)                                               - 55                              P = 0.002 
     Diabetes (new definition, n = 483)                     - 42                              P = 0.001 
     IGT (n =675)                                                       - 40                              P = 0.001 
CARE  
     All participants (N = 4159)                                 - 24                              P = 0.003 
     Diabetes (n = 586)                                              - 25                              P = 0.05 
LIPID  
     All participants (N =9014)                                  - 24                              P < 0.001 
     Diabetes (n = 782)                                              - 19                                   NS 
Primary prevention 
WOSCOPS 
     All participants (N = 6595)                                 - 31                              P < 0.001 
     Diabetes (n = 76)                                                  Numbers too small for analysis 
AFCAPS/TexCAPS 
     All participants (N = 6605)                                 - 37                              P < 0.001 
    Diabetes (n = 155)                                               Numbers too small for analysis 
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Table 1.7 Clinical events trials of fibrate drugs involving patients with diabetes 
 
Helsinki Heart Study                                                 Change in CHD risk on active      
                                                                                            treatment in 5 years 
       Whole study (4081 participants)                                               - 34%  
                                                                                                          P < 0.02 
       Diabetes (135 participants)                                          - 68% (total events = 10)      
                                                                                                            NS 
SENDCAP (Elkeles, et. al, 1998)                                     Change in CHD risk on active    
                                                                                               treatment in 3 years 
       Diabetes (164 participants)                                                             - 67 %                   
                                                                                                               P = 0.01 
 
 
In the Veterans Affairs High-Density Lipoprotein Cholesterol InterventionTrial 
(VA-HIT), Gemfibrozil was associated with a 24 % decrease in cardiovascular events in 
diabetic subjects with prior cardiovascular disease (Rubins et. al, 1999). In the 
Lipoprotein and Coronary Atherosclerosis Study (LCAS) 339 patients with mildly to 
moderately elevated LDL cholesterol (68 had baseline HDL cholesterol > 0.91 mmol/L, 
mean 0.82 ± 0.06 mmol/L versus 1.23 ± 0.29 mmol/L in 271 patients with baseline 
HDL cholesterol ≤ 0.91 mmol/L), were randomized for placebo and Fluvastatin 
treatment to compare angiographic progression and the benefits of the Fluvastatin in 
patients with low versus patients with higher HDL cholesterol. In placebo group, 
patients with low HDL cholesterol had significantly more angiographic progression than 
patients with higher HDL cholesterol. Angiographic progression was significantly 
reduced among low-HDL cholesterol patients than higher-HDL cholesterol patients in 
the treatment group (Ballantyne et. al, 1999). Each 1 mg/dl increase in HDL cholesterol 
was associated with 2 % (men) and 3 % (women) reduction in risk for coronary artery 
disease events (Gordon et. al, 1989; Ballantyne et. al, 1999; Howard et. al, 2000).  
